Hjem › Blodcancer › Oklahoma
Blodcancer kliniske forsøg i Oklahoma
8 studier for Blodcancer søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082), Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. sep. 2026 · NCT04242095Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- OU Health Physicians - Infectious Disease Clinic, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT06665100A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 2 til 18 · Alle køn · Opdateret 5. maj 2026 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.